# Chronic Kidney Disease Prognosis Consortium (CKD-PC)

> **NIH NIH R01** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2024 · $835,918

## Abstract

PROJECT SUMMARY/ABSTRACT
This proposal details work for the third cycle (2023-2028) of the Chronic Kidney Disease Prognosis Consortium
(CKD-PC). A global public health problem, CKD affects >10% of the world population and is a leading cause of
death. The CKD-PC – a global group of ~300 investigators representing >100 cohorts with >30 million
individuals from >40 countries – has played an important role in facilitating major advances in the staging of
CKD, the identification of surrogate endpoint for clinical trials, and the establishment of a range of risk tools for
use in clinical care (ckdpc.org). The CKD-PC uses an efficient, fluid consortium structure, centralized analytics,
and innovative meta-analysis methods to advance epidemiologic research in CKD prognosis at the highest
level of rigor, productivity, and clinical impact. In this phase, we aim to inform guidelines in kidney disease with
evidence on CKD prevalence and progression; elucidate the role of CKD in the risk of heart failure,
arrhythmias, infections, cancer, frailty, and dementia; and evaluate the performance of kidney and CKD-related
risk tools in different clinical settings. Current challenges include: quantifying the implications of the 2021 CKD-
EPI equations world-wide; determining when and how often cystatin C should be tested; and identifying
situations in which local adaptations of risk calculators for kidney and CKD-related outcomes are warranted.
We will work to continue to increase regional representation, enhancing generalizability, and to incorporate
additional clinical trials in order to map observed risks to real-world data to inform guideline-recommended
thresholds for treatment. We remain flexible and efficient in responding to high priority topics set forth by
guideline organizations and regulatory bodies such as the US Food and Drug Administration, and for
collaboration with other consortia, including the Global Burden of Disease. Our overarching aim is to improve
the health of patients with or at risk for CKD.

## Key facts

- **NIH application ID:** 10898781
- **Project number:** 5R01DK100446-12
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** JOSEF CORESH
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $835,918
- **Award type:** 5
- **Project period:** 2023-11-15 → 2028-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10898781

## Citation

> US National Institutes of Health, RePORTER application 10898781, Chronic Kidney Disease Prognosis Consortium (CKD-PC) (5R01DK100446-12). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10898781. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*